Public company intelligence preview
ALLOGENE THERAPEUTICS INC
38 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $5.4M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 169 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Allogene Therapeutics Inc. is a Healthcare sector, Biotechnology company focused on clinical-stage, allogeneic “off-the-shelf” CAR T therapies for cancer and autoimmune diseases. Its lead programs are cema-cel for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune indications, with near-term value tied to clinical readouts rather than commercial sales. The company’s integrated manufacturing strategy, centered on its Cell Forge 1 facility in California, is meant to support scalable production and eventual commercialization. Because it is still pre-commercial, the business is highly dependent on clinical success, regulatory approvals, and intellectual property protection.
Executive Compensation Practices
In a biotechnology company like Allogene, executive compensation is typically driven by development milestones rather than revenue growth or earnings, since the company remains in a loss-making, clinical-stage profile. Incentives are likely tied to clinical execution, regulatory progress, manufacturing readiness, and cash management, especially given the company’s large accumulated deficit and ongoing operating losses. The 2025 reductions in R&D, G&A, and workforce levels suggest compensation programs may also emphasize cost discipline and prioritization of lead assets. Stock-based compensation is especially important in this sector, and the filing summaries indicate it is a meaningful expense component that can influence both reported results and executive incentive design.
Insider Trading Considerations
Insider trading patterns in Allogene should be viewed through the lens of binary clinical catalysts, including the ALPHA3 futility analysis and ALLO-329 proof-of-concept data, which can create sharp share-price reactions. Because the company’s valuation is tied to trial outcomes, manufacturing execution, and FDA milestones, insiders may be especially sensitive to blackout periods around data releases and regulatory updates. Trading activity may also reflect financing needs, since the company has relied on ATM sales, prior offerings, and collaborations to fund operations into the later part of 2027. For researchers and traders, insider purchases or sales may be less about near-term financial performance and more about management’s confidence in clinical data, partnership prospects, and the company’s ability to extend its cash runway.
Unlock the full ALLO insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.